• FirefoxUpgrade to the new Firefox »
  •  Dow Up2.43% Nasdaq Up2.24%

    Alexion Pharmaceuticals, Inc. (ALXN)

    -NasdaqGS
    188.96 Up 6.88(3.78%) Dec 18, 4:00PM EST
    |After Hours : 188.96 0.00 (0.00%) Dec 18, 6:19PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Alexion Pharmaceuticals, Inc.
    352 Knotter Drive
    Cheshire, CT 06410
    United States - Map
    Phone: 203-272-2596
    Fax: 203-271-8198
    Website: http://www.alexionpharm.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:1,774

    Business Summary 

    Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Alexion Pharmaceuticals, Inc.

    Corporate Governance 
    Alexion Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 7. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 8; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Leonard Bell M.D., 56
    Co-Founder, Chairman and Chief Exec. Officer
    3.62M21.84M
    Dr. Stephen P. Squinto Ph.D., 58
    Co-Founder, Chief Global Operations Officer and Exec. VP
    1.13M12.24M
    Dr. Joseph A. Madri Ph.D., M.D., 67
    Co-Founder
    85.00KN/A
    Mr. Vikas Sinha M.B.A., C.A., CPA, 51
    Chief Financial Officer and Exec. VP
    1.31M16.10M
    Mr. David L. Hallal , 48
    Chief Operating Officer and Director
    1.38M16.58M
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders